Literature DB >> 15531484

Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension.

Hoong Sern Lim1, Gregory Y H Lip, Andrew D Blann.   

Abstract

Although the metabolic syndrome is associated with endothelial damage/dysfunction, the effect of risk factors and their relationship with the development of this condition are unclear. We hypothesized that plasma von Willebrand factor (vWf, marking endothelial damage/dysfunction) increases with the number of components of metabolic syndrome and that increased levels precede its development. To test this, fasting vWf, glucose and lipids were measured in 161 patients (mean age 63 +/- 7 yr, 85% males) with hypertension. Using World Health Organization (WHO) criteria, 32 (19.9%), and using National Cholesterol Education Program (NCEP) criteria, 70 (43.5%) had metabolic syndrome. Plasma vWf was higher in these patients regardless of defining criteria and increased with the number of the components of metabolic syndrome (both P < 0.001). After 4 yr, patients who did not have metabolic syndrome at baseline were reassessed for the development of this condition. Of the 129 patients who did not meet the WHO criteria at baseline, 38 (29.5%) subsequently developed the condition, whereas 36 of the 91 (39.6%) who did not meet the NCEP criteria at baseline subsequently developed metabolic syndrome. Baseline vWf levels did not predict development of metabolic syndrome, regardless of criteria (P = 0.071 for WHO and P = 0.639 for NCEP). Our data suggest more severe endothelial damage/dysfunction with cumulative metabolic syndrome-related risk factors. The failure of plasma vWf to predict the development of metabolic syndrome suggests that endothelial damage/dysfunction is a consequence, not a cause, of these risk factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531484     DOI: 10.1210/jc.2004-0616

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters.

Authors:  Assimina Galli-Tsinopoulou; Ioannis Kyrgios; Ioanna Maggana; Eleni Z Giannopoulou; Eleni P Kotanidou; Charilaos Stylianou; Emmanouil Papadakis; Ioannis Korantzis; George Varlamis
Journal:  Eur J Pediatr       Date:  2010-12-08       Impact factor: 3.183

2.  Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation.

Authors:  George I Varughese; Jeetesh V Patel; Joseph Tomson; Gregory Y H Lip
Journal:  Heart       Date:  2006-09-27       Impact factor: 5.994

3.  Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.

Authors:  Mariya H Apostolova; Craig D Seaman; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-21       Impact factor: 2.389

4.  The association between metabolic syndrome and vascular endothelial dysfunction in adolescents.

Authors:  Ying Wei; Geli Liu; Jingyan Yang; Rongxiu Zheng; Lihong Jiang; Pengli Bao
Journal:  Exp Ther Med       Date:  2013-04-09       Impact factor: 2.447

5.  Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.

Authors:  Bai-Bing Yang; Zhi-Wei Hong; Zheng Zhang; Wen Yu; Tao Song; Lei-Lei Zhu; He-Song Jiang; Guo-Tao Chen; Yun Chen; Yu-Tian Dai
Journal:  Int J Impot Res       Date:  2018-09-13       Impact factor: 2.896

6.  Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine.

Authors:  Bernhard Lämmle
Journal:  Thromb Haemost       Date:  2021-02-18       Impact factor: 6.681

7.  Implication of Free Fatty Acids in Thrombin Generation and Fibrinolysis in Vascular Inflammation in Zucker Rats and Evolution with Aging.

Authors:  Jérémy Lagrange; Mélusine Didelot; Amel Mohamadi; Lucy A Walton; Saartje Bloemen; Bas de Laat; Huguette Louis; Simon N Thornton; Brian Derby; Michael J Sherratt; Bruno Fève; Pascal Challande; Riaz Akhtar; J Kennedy Cruickshank; Patrick Lacolley; Véronique Regnault
Journal:  Front Physiol       Date:  2017-11-22       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.